Navigation Links
Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Date:1/10/2008

, it is estimated that approximately 40% of people aged 65 and above, or 16 million, have AAMI. It is characterized by gradual memory impairment (subjective memory decline and objective memory loss) with the absence of dementia. Individuals with AAMI have been shown to have a three-fold greater risk for development of dementia than individuals who do not meet AAMI criteria.

About Amarin

Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has two proprietary technology platforms, a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation.

Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively.

Disclosure Notice

The information contained in this document is as of January 10, 2008. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking statements about Amarin's financial condition, results of operations, business prospects and products in research that involve
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. Amarin Signs Agreement to Acquire Ester Neurosciences
6. NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that it will ... May 7, 2015 after the close of the U.S. ... and webcast on Thursday, May 7, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:4/30/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... contract R&D services provider, today announced that its board ... dated April 29, 2015, from a consortium (the "Consortium") ... founder, chairman and chief executive officer of the Company, ... a transaction (the "Transaction") involving the acquisition of all ...
(Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Phytomer’s DOUCEUR ... sensitive and reactive skin while battling the weakening ... This restorative cream is formulated with star ingredient ... via biotechnology in a complex of soothing minerals ...
(Date:4/30/2015)... 2015 Clinovo Staffing Solutions ... Conference held in Orlando, FL on May 17-20th, ... with Leslie Kolman, Manager of Staffing Solutions, will present ... at Booth #17. , “We are excited to ... year”, Says Trisha Heredia, Senior Director of Staffing Solutions ...
Breaking Biology Technology:Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3
... 9 NuVasive, Inc. (Nasdaq:,NUVA), a medical device company ... the spine, announced today,that Kevin O,Boyle, Executive Vice President ... William Blair 28th Annual Growth Stock,Conference at the Four ... 8:30 a.m. CT., A live Web cast of ...
... ... Emphasizes Strategic Growth Plan and Capital Markets Interaction ... -, NEW ... a pharmaceutical,company dedicated to improving health through the development, manufacture,and commercialization of a broad range ...
... 9 ChanTest, the leading provider of ion,channel ... a completely redesigned Web site at http://www.ChanTest.com ... and CEO of ChanTest, the,company,s goal was to ... significant improvements in content, navigation, and visual,appeal. "The ...
Cached Biology Technology:NuVasive to Present at William Blair 28th Annual Growth Stock Conference 2NuVasive to Present at William Blair 28th Annual Growth Stock Conference 3American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 2American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 3ChanTest Launches Redesigned Web Site 2
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Edythe Broad Center of Regenerative Medicine and Stem Cell ... (blood-producing) stem cells from the bone marrow of patients ... study was led by Dr. Donald Kohn, professor of ... Sickle cell disease causes the body to ...
... wide range of problems from arthritis to cardiovascular disease, and ... problem. A new research report appearing in the July 2013 ... explain why DHA is important in reducing inflammation, and provides ... bring people back to optimal health. Specifically, researchers found that ...
... from cells of the embryonic nervous system. The ... range from spontaneous regression to fatal outcomes. Highly ... and overcoming the resistance mechanisms of highly aggressive ... effective treatments. Scientists from the department ...
Cached Biology News:UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials 2Harvard and USC scientists show how DHA resolves inflammation 2Neuroblastoma: Autophagy protects from chemotherapy 2
... Series offers high performance miniature stepper motors ... and 34 frame sizes. These space-efficient 1.8 ... science applications, including medical instrumentation, medical devices, ... systems., Meets a wide range of ...
... for a single fragment based screening project: , ... 96 shape-diverse mixtures of 4 (5 uL ... for structure refinement , Individual compounds are ... at ca. 50 mM. Supplied in 5 96-well trays. ...
... combine the proven features of the pET, ... provides all of the benefits and versatility ... backbone. The pTriEx vectors have been extensively ... in all three expression systems. In each ...
... first instrument engineered to match the speed ... thousands of research centers worldwide. It uses ... are ideally suited for high-speed temperature cycling ... high surface-area-to-volume ratio. ,By combining glass capillary ...
Biology Products: